194 related articles for article (PubMed ID: 35129210)
1. Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey.
DiStefano MJ; Alexander GC; Polsky D; Anderson GF
J Am Geriatr Soc; 2022 Jun; 70(6):1685-1694. PubMed ID: 35129210
[TBL] [Abstract][Full Text] [Related]
2. Making the Case for Accelerated Withdrawal of Aducanumab.
Whitehouse P; Gandy S; Saini V; George DR; Larson EB; Alexander GC; Avorn J; Brownlee S; Camp C; Chertkow H; Fugh-Berman A; Howard R; Kesselheim A; Langa KM; Perry G; Richard E; Schneider L
J Alzheimers Dis; 2022; 87(3):1003-1007. PubMed ID: 35404287
[TBL] [Abstract][Full Text] [Related]
3. Physician Perspectives on the Food and Drug Administration's Decision to Grant Accelerated Approval to Aducanumab for Alzheimer's Disease.
Dhruva SS; Kesselheim AS; Woloshin S; Ji RZ; Lu Z; Darrow JJ; Redberg RF
Clin Pharmacol Ther; 2023 Sep; 114(3):614-617. PubMed ID: 37218658
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's and Aducanumab: Unjust Profits and False Hopes.
Fleck LM
Hastings Cent Rep; 2021 Jul; 51(4):9-11. PubMed ID: 34156732
[TBL] [Abstract][Full Text] [Related]
5. Lessons Learned from Approval of Aducanumab for Alzheimer's Disease.
Heidebrink JL; Paulson HL
Annu Rev Med; 2024 Jan; 75():99-111. PubMed ID: 38285515
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US.
Ross EL; Weinberg MS; Arnold SE
JAMA Neurol; 2022 May; 79(5):478-487. PubMed ID: 35344024
[TBL] [Abstract][Full Text] [Related]
7. Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?
Schulman KA; Greicius MD; Richman B
JAMA; 2021 Aug; 326(5):383-384. PubMed ID: 34279572
[No Abstract] [Full Text] [Related]
8. Variation in Medicaid and commercial payer coverage of aducanumab for Alzheimer's disease.
Lin PJ; Levine A; Rucker J; Chambers JD
Alzheimers Dement; 2023 Aug; 19(8):3654-3669. PubMed ID: 36852834
[TBL] [Abstract][Full Text] [Related]
9. Controversial Approval of New Drug to Treat Alzheimer's Disease.
Aschenbrenner DS
Am J Nurs; 2021 Oct; 121(10):22-23. PubMed ID: 34554982
[TBL] [Abstract][Full Text] [Related]
10. Making the Case for the Accelerated Withdrawal of Aducanumab.
Whitehouse PJ; Saini V
J Alzheimers Dis; 2022; 87(3):999-1001. PubMed ID: 35491796
[TBL] [Abstract][Full Text] [Related]
11. Is Aducanumab for LMICs? Promises and Challenges.
Gunawardena IPC; Retinasamy T; Shaikh MF
Brain Sci; 2021 Nov; 11(11):. PubMed ID: 34827546
[TBL] [Abstract][Full Text] [Related]
12. An insider's perspective on FDA approval of aducanumab.
Wang Y
Alzheimers Dement (N Y); 2023; 9(2):e12382. PubMed ID: 37215506
[TBL] [Abstract][Full Text] [Related]
13. Accelerated Approval of Aducanumab: Where Do We Stand Now?
Barenholtz Levy H
Ann Pharmacother; 2022 Jun; 56(6):736-739. PubMed ID: 34595939
[TBL] [Abstract][Full Text] [Related]
14. Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development.
Brockmann R; Nixon J; Love BL; Yunusa I
Lancet Reg Health Am; 2023 Apr; 20():100467. PubMed ID: 36908502
[TBL] [Abstract][Full Text] [Related]
15. Practical Considerations in the Administration of Aducanumab for the Neurologist.
Coerver K; Yu MM; D'Abreu A; Wasserman M; Nair KV
Neurol Clin Pract; 2022 Apr; 12(2):169-175. PubMed ID: 35733944
[TBL] [Abstract][Full Text] [Related]
16. Aducanumab for the treatment of Alzheimer's disease: a systematic review.
Rahman A; Hossen MA; Chowdhury MFI; Bari S; Tamanna N; Sultana SS; Haque SN; Al Masud A; Saif-Ur-Rahman KM
Psychogeriatrics; 2023 May; 23(3):512-522. PubMed ID: 36775284
[TBL] [Abstract][Full Text] [Related]
17. The Medicolegal and Ethical Dimensions of Physician Prescription Reluctance.
Rose RV; Kass JS
Continuum (Minneap Minn); 2022 Jun; 28(3):937-941. PubMed ID: 35678410
[TBL] [Abstract][Full Text] [Related]
18. Aducanumab Fails to Produce Efficacy Results Yet Obtains US Food and Drug Administration Approval.
Angelo M; Ward L
Popul Health Manag; 2021 Dec; 24(6):638-639. PubMed ID: 34516238
[No Abstract] [Full Text] [Related]
19. Effect of Aducanumab Approval on Willingness to Participate in Preclinical Alzheimer's Disease Trials.
Ritchie M; Witbracht M; Nuño MM; Hoang D; Gillen DL; Grill JD
J Alzheimers Dis; 2022; 90(3):1291-1300. PubMed ID: 36245381
[TBL] [Abstract][Full Text] [Related]
20. Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data.
Høilund-Carlsen PF; Alavi A
J Alzheimers Dis; 2021; 84(4):1457-1460. PubMed ID: 34657891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
